PF-Atlas › Clinical Trials › NCT04553419
Antibiotic Treatment Of Staphylococcus Aureus In Stable People With CF
Cephalexin · Phase 3
Registry ID
NCT04553419
Phase
Phase 3
Status
Unknown
Drug / intervention
Cephalexin
Sponsor
University of British Columbia
Start
2020-07-27
Enrollment
86
Locations
2
About this trial
This is a randomized, double-blinded study that aims to assess the effect of an oral antibiotic called Cephalexin (150 mg/kg/day) compared to placebo in clinically stable children with cystic fibrosis who have grown a bacteria called MSSA (methicillin-susceptible Staphylococcus aureus) over the course of 2 weeks. A sensitive technique called MBW (multiple breath washout) will be used to look at how well the participants lungs are functioning during the study and to see if the antibiotic improves function. The primary outcome of the study will be the relative change in the MBW measurement (LCI2.5) between day 0 and day 14 of study treatment.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT04553419 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.